Cue Biopharma, Inc. (CUE) 10-Year Financial Performance & Capital Metrics

CUE • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

AboutCue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; CUE-103 a CUE-100 series Immuno-STAT targeting the KRAS G12V mutation, including colorectal carcinoma, lung cancer, and pancreatic cancer; CUE-200 that focuses on cell surface receptors, including CD80 and/or 4-1BBL to address T cell exhaustion associated with chronic infections; and CUE-300 and CUE-400 framework to target various autoimmune diseases. Cue Biopharma, Inc. has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for the development of Immuno-STATs focused on the field of oncology; and Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Show more

Revenue $9M +69.2%
EBITDA -$39M +19.6%
Net Income -$41M +19.8%
EPS (Diluted) -0.72 +35.1%
Gross Margin 100% +116.8%
EBITDA Margin -421.56% +52.5%
Operating Margin -446.86% +53.0%
Net Margin -437.97% +52.6%
ROE -149.03% -50.9%
ROIC -866.75% -306.1%
Debt/Equity 0.51 +28.0%
Interest Coverage -52.14 -24.5%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong 5Y sales CAGR of 21.8%
✓Trading at only 0.9x book value

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Weak momentum: RS Rating 4 (bottom 4%)
✗Shares diluted 23.1% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y21.84%

3Y-14.66%

TTM-25.51%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM15.53%

EPS CAGR

10Y-

5Y-

3Y-

TTM49.02%

ROCE

10Y Avg-71.46%

5Y Avg-81.28%

3Y Avg-95.55%

Latest-131.85%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.33B	9.92	70.86	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	720.1M	4.25	11.18	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	881.27M	2.22	-1.73	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	572.64M	7.30	-2.38			-117.82%	0.18
NKTRNektar Therapeutics	719.28M	35.36	-4.07	9.22%	-192.87%	-141.9%	1.69
IMNMImmunome, Inc.	2.52B	22.85	-4.57	-35.5%	-23.01%	-84.4%	0.03
IBRXImmunityBio, Inc.	3.89B	3.95	-6.37	22.71%	-422.28%
NRIXNurix Therapeutics, Inc.	1.91B	18.86	-6.55	-29.15%	-292.5%	-65.76%	0.05

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	1.14M	3.46M	3.15M	14.94M	1.25M	5.49M	9.29M
Revenue Growth %	-	-	-	-	2.03%	-0.09%	3.74%	-0.92%	3.41%	0.69%
Cost of Goods Sold+	44.81K	202.09K	419.57K	28.54M	27.49M	33.55M	-1.78M	0	38.1M	0
COGS % of Revenue	-	-	-	24.98%	7.95%	10.63%	-0.12%	-	6.94%	-
Gross Profit+	-44.81K	-202.09K	-419.57K	-27.4M	-24.03M	-30.39M	16.72M	1.25M	-32.61M	9.29M
Gross Margin %	-	-	-	-23.98%	-6.95%	-9.63%	1.12%	1%	-5.94%	1%
Gross Profit Growth %	-	-3.51%	-1.08%	-64.31%	0.12%	-0.26%	1.55%	-0.93%	-27.19%	1.28%
Operating Expenses+	1.93M	7.66M	23.23M	39.84M	12.74M	14.65M	60.43M	54.47M	19.54M	50.79M
OpEx % of Revenue	-	-	-	34.87%	3.68%	4.64%	4.04%	43.75%	3.56%	5.47%
Selling, General & Admin	425.08K	1.97M	4.33M	11.3M	12.74M	14.65M	17.31M	16.17M	16.68M	14.59M
SG&A % of Revenue	-	-	-	9.89%	3.68%	4.64%	1.16%	12.99%	3.04%	1.57%
Research & Development	1.5M	5.69M	18.9M	28.54M	27.49M	33.55M	41.35M	38.58M	40.8M	36.3M
R&D % of Revenue	-	-	-	24.98%	7.95%	10.63%	2.77%	30.99%	7.43%	3.91%
Other Operating Expenses	0	0	0	165.34K	-27.49M	-33.55M	1.78M	-277K	-37.94M	-93K
Operating Income+	-1.93M	-7.66M	-23.23M	-38.7M	-36.77M	-45.04M	-43.71M	-53.23M	-52.15M	-41.5M
Operating Margin %	-	-	-	-33.87%	-10.63%	-14.28%	-2.93%	-42.75%	-9.5%	-4.47%
Operating Income Growth %	-	-2.97%	-2.03%	-0.67%	0.05%	-0.23%	0.03%	-0.22%	0.02%	0.2%
EBITDA+	-1.88M	-7.46M	-22.81M	-37.94M	-35.96M	-43.99M	-45.49M	-51.42M	-48.71M	-39.15M
EBITDA Margin %	-	-	-	-33.2%	-10.4%	-13.94%	-3.04%	-41.3%	-8.87%	-4.22%
EBITDA Growth %	-	-2.96%	-2.06%	-0.66%	0.05%	-0.22%	-0.03%	-0.13%	0.05%	0.2%
D&A (Non-Cash Add-back)	44.81K	202.09K	419.57K	760.01K	810.78K	1.06M	-1.78M	1.81M	3.44M	2.35M
EBIT	-1.93M	-7.66M	-23.23M	-38.7M	-36.77M	-45.04M	-43.67M	-52.3M	-49.49M	-39.88M
Net Interest Income+	0	0	0	376.01K	482.79K	463.91K	45.9K	215K	1.42M	826K
Interest Income	0	52	35	376.01K	419K	463.91K	45.9K	928.24K	2.66M	1.62M
Interest Expense	0	0	0	0	0	0	0	713.82K	1.25M	796K
Other Income/Expense	0	52	35	541.35K	482.79K	463.91K	45.9K	215K	1.42M	826K
Pretax Income+	-1.93M	-7.66M	-23.23M	-38.16M	-36.29M	-44.58M	-43.67M	-53.01M	-50.73M	-40.67M
Pretax Margin %	-	-	-	-33.39%	-10.49%	-14.13%	-2.92%	-42.58%	-9.24%	-4.38%
Income Tax+	0	0	0	825K	412.5K	206.25K	495K	0	0	0
Effective Tax Rate %	1%	1%	1%	1.02%	1.01%	1%	1.01%	1%	1%	1%
Net Income+	-1.93M	-7.66M	-23.23M	-38.98M	-36.7M	-44.78M	-44.16M	-53.01M	-50.73M	-40.67M
Net Margin %	-	-	-	-34.12%	-10.61%	-14.2%	-2.96%	-42.58%	-9.24%	-4.38%
Net Income Growth %	-	-2.97%	-2.03%	-0.68%	0.06%	-0.22%	0.01%	-0.2%	0.04%	0.2%
Net Income (Continuing)	-1.93M	-7.66M	-23.23M	-38.98M	-36.7M	-44.78M	-44.16M	-53.01M	-50.73M	-40.67M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.26	-0.37	-1.13	-1.94	-1.66	-1.56	-1.41	-1.49	-1.11	-0.72
EPS Growth %	-	-0.42%	-2.05%	-0.72%	0.14%	0.06%	0.1%	-0.06%	0.26%	0.35%
EPS (Basic)	-0.26	-0.37	-1.13	-1.94	-1.66	-1.56	-1.41	-1.49	-1.11	-0.72
Diluted Shares Outstanding	7.35M	20.64M	20.64M	20.13M	22.04M	28.69M	31.29M	35.65M	45.75M	56.33M
Basic Shares Outstanding	7.35M	20.64M	20.64M	20.13M	22.04M	28.69M	31.29M	35.65M	45.75M	56.33M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	6.51M	15.14M	65.07M	40.61M	61.02M	87.53M	68.47M	77.19M	51.45M	25.14M
Cash & Short-Term Investments	6.46M	14.98M	63.58M	39.21M	59.41M	84.87M	64.37M	76.29M	48.51M	23.39M
Cash Only	6.41M	14.93M	63.53M	20.8M	44.29M	74.87M	64.37M	51.61M	48.51M	22.46M
Short-Term Investments	50K	50.03K	50.07K	18.41M	15.12M	10M	0	24.68M	0	929K
Accounts Receivable	0	0	0	0	754.9K	1.42M	3.14M	57K	1.7M	945K
Days Sales Outstanding	-	-	-	-	79.67	164.02	76.77	16.71	112.89	37.14
Inventory	0	0	225.5K	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	196.17	-	-	-	-	-	-	-
Other Current Assets	0	0	453.49K	104.07K	0	0	0	841K	1.24M	0
Total Non-Current Assets+	807.97K	1.14M	1.89M	4.75M	10.58M	12.01M	14.93M	14.1M	10.08M	7.05M
Property, Plant & Equipment	709.47K	1.02M	1.69M	2.78M	7.18M	8.88M	11.92M	10.7M	7.12M	4.84M
Fixed Asset Turnover	-	-	-	0.41x	0.48x	0.36x	1.25x	0.12x	0.77x	1.92x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	175K	0	11.67K	0	0	0	0	0
Long-Term Investments	0	0	0	150K	0	0	150K	0	151K	0
Other Non-Current Assets	98.5K	117K	23.28K	1.82M	3.38M	3.12M	2.86M	3.39M	2.81M	2.21M
Total Assets+	7.31M	16.28M	66.95M	45.36M	71.61M	99.53M	83.4M	91.28M	61.53M	32.19M
Asset Turnover	-	-	-	0.03x	0.05x	0.03x	0.18x	0.01x	0.09x	0.29x
Asset Growth %	-	1.23%	3.11%	-0.32%	0.58%	0.39%	-0.16%	0.09%	-0.33%	-0.48%
Total Current Liabilities+	342.2K	1.07M	5.35M	6.22M	11.66M	16.32M	12.79M	11.55M	17.08M	13.69M
Accounts Payable	139.63K	523.81K	1.33M	2.04M	882.67K	2.07M	2.59M	2.73M	3.5M	2.82M
Days Payables Outstanding	1.14K	946.09	1.16K	26.03	11.72	22.53	-531.84	-	33.54	-
Short-Term Debt	0	0	0	0	0	0	1.97M	1.96M	3.96M	4.33M
Deferred Revenue (Current)	0	0	623.85K	1000K	0	1000K	645.35K	0	1000K	0
Other Current Liabilities	45.45K	109.09K	2.54M	1.58M	4.1M	1.96M	38.31K	2.27M	1.92M	85K
Current Ratio	19.01x	14.18x	12.17x	6.53x	5.24x	5.36x	5.35x	6.68x	3.01x	1.84x
Quick Ratio	19.01x	14.18x	12.13x	6.53x	5.24x	5.36x	5.35x	6.68x	3.01x	1.84x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	34.09K	36.36K	0	5.17M	5.37M	4.31M	5.12M	14.05M	7.36M	1M
Long-Term Debt	0	0	0	0	0	0	0	8.04M	4.2M	0
Capital Lease Obligations	0	0	0	0	1.35M	2.37M	5.12M	6.02M	3.16M	1M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	34.09K	36.36K	0	0	4.02M	0	0	0	0	1
Total Liabilities	376.3K	1.1M	5.35M	11.39M	17.02M	20.62M	17.91M	25.6M	24.45M	14.69M
Total Debt+	0	0	2.5M	0	5.8M	7.15M	12.02M	19.32M	14.7M	8.88M
Net Debt	-6.41M	-14.93M	-61.03M	-20.8M	-38.49M	-67.72M	-52.35M	-32.3M	-33.82M	-13.58M
Debt / Equity	-	-	0.04x	-	0.11x	0.09x	0.18x	0.29x	0.40x	0.51x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-	-	-74.56x	-41.89x	-52.14x
Total Equity+	6.94M	15.17M	61.61M	33.97M	54.58M	78.91M	65.49M	65.68M	37.09M	17.5M
Equity Growth %	-	1.19%	3.06%	-0.45%	0.61%	0.45%	-0.17%	0%	-0.44%	-0.53%
Book Value per Share	0.94	0.74	2.98	1.69	2.48	2.75	2.09	1.84	0.81	0.31
Total Shareholders' Equity	6.94M	15.17M	61.61M	33.97M	54.58M	78.91M	65.49M	65.68M	37.09M	17.5M
Common Stock	7.35K	10.64K	20.13K	20.7K	26.56K	30.35K	32.2K	43K	47K	62K
Retained Earnings	-1.93M	-9.59M	-32.82M	-71.8M	-108.5M	-153.29M	-197.45M	-250.46M	-301.19M	-341.86M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-44.81K	-246.9K	-661.15K	-10.96K	-10.32K	7.13K	0	-96K	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-1.66M	-5.97M	-12.19M	-26.41M	-30.8M	-32.49M	-38.84M	-41.81M	-39.96M	-36.33M
Operating CF Margin %	-	-	-	-23.11%	-8.91%	-10.3%	-2.6%	-33.58%	-7.28%	-3.91%
Operating CF Growth %	-	-2.6%	-1.04%	-1.17%	-0.17%	-0.06%	-0.2%	-0.08%	0.04%	0.09%
Net Income	-1.93M	-7.66M	-23.23M	-38.98M	-36.7M	-44.78M	-44.16M	-53.01M	-50.73M	-40.67M
Depreciation & Amortization	44.81K	202.09K	419.57K	760.01K	5.17M	-3.15M	-1.78M	1.81M	3.44M	2.35M
Stock-Based Compensation	0	889.56K	2.78M	7.17M	6.52M	10.48M	11.52M	9.5M	8.18M	6.85M
Deferred Taxes	0	0	10.68K	79.86K	-18.19K	0	0	0	0	0
Other Non-Cash Items	79.55K	65.91K	4.93M	345.1K	-4.28M	-479.54K	-26.13K	-454K	90K	74K
Working Capital Changes	146.8K	532.32K	2.91M	4.21M	-1.49M	5.43M	-4.39M	356K	-934K	-4.92M
Change in Receivables	0	0	0	0	-754.9K	-662.58K	-1.73M	3.08M	-1.64M	753K
Change in Inventory	0	0	0	0	-509.8K	0	0	0	0	0
Change in Payables	177.81K	0	561.59K	376.15K	-1.15M	741.26K	520.4K	83K	770K	-678K
Cash from Investing+	-804.29K	-516.01K	-1.2M	-20.35M	3.45M	4.46M	9.11M	-24.61M	25M	32K
Capital Expenditures	-754.29K	-515.98K	-1.2M	-1.85M	-46.35K	-595.26K	-913.04K	-171K	0	-66K
CapEx % of Revenue	-	-	-	1.62%	0.01%	0.19%	0.06%	0.14%	-	0.01%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-50K	-33	-35	-18.5M	0	0	21.55K	6K	2K	98K
Cash from Financing+	8.87M	15.01M	62M	4.18M	50.79M	58.61M	19.23M	53.66M	11.86M	10.24M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	1K	0	9.01K	12.5K	1.79M	1.93M	1.85M	4.36M	473K	18K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-2.41M	-6.48M	-13.4M	-28.27M	-30.84M	-33.09M	-39.75M	-41.98M	-39.96M	-36.4M
FCF Margin %	-	-	-	-24.74%	-8.92%	-10.49%	-2.66%	-33.72%	-7.28%	-3.92%
FCF Growth %	-	-1.69%	-1.07%	-1.11%	-0.09%	-0.07%	-0.2%	-0.06%	0.05%	0.09%
FCF per Share	-0.33	-0.31	-0.65	-1.40	-1.40	-1.15	-1.27	-1.18	-0.87	-0.65
FCF Conversion (FCF/Net Income)	0.86x	0.78x	0.52x	0.68x	0.84x	0.73x	0.88x	0.79x	0.79x	0.89x
Interest Paid	0	0	0	0	0	0	0	570K	1M	669K
Taxes Paid	0	0	0	825K	412.5K	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-27.8%	-69.27%	-60.52%	-81.57%	-82.88%	-67.1%	-61.16%	-80.82%	-98.73%	-149.03%
Return on Invested Capital (ROIC)	-	-1469.1%	-4237.96%	-422.31%	-188.49%	-247.66%	-269.45%	-171.6%	-213.43%	-866.75%
Gross Margin	-	-	-	-2398.16%	-694.82%	-963.48%	111.9%	100%	-593.93%	100%
Net Margin	-	-	-	-3411.53%	-1061.18%	-1419.79%	-295.56%	-4257.83%	-924.1%	-437.97%
Debt / Equity	-	-	0.04x	-	0.11x	0.09x	0.18x	0.29x	0.40x	0.51x
Interest Coverage	-	-	-	-	-	-	-	-74.56x	-41.89x	-52.14x
FCF Conversion	0.86x	0.78x	0.52x	0.68x	0.84x	0.73x	0.88x	0.79x	0.79x	0.89x
Revenue Growth	-	-	-	-	202.67%	-8.79%	373.68%	-91.67%	340.96%	69.16%

Frequently Asked Questions

Growth & Financials

Cue Biopharma, Inc. (CUE) reported $7.1M in revenue for fiscal year 2024.

Cue Biopharma, Inc. (CUE) grew revenue by 69.2% over the past year. This is strong growth.

Cue Biopharma, Inc. (CUE) reported a net loss of $37.7M for fiscal year 2024.

Dividend & Returns

Cue Biopharma, Inc. (CUE) has a return on equity (ROE) of -149.0%. Negative ROE indicates the company is unprofitable.

Cue Biopharma, Inc. (CUE) had negative free cash flow of $29.8M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Cue Biopharma, Inc. (CUE) 10-Year Financial Performance & Capital Metrics

CUE • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

Revenue $9M +69.2%
EBITDA -$39M +19.6%
Net Income -$41M +19.8%
EPS (Diluted) -0.72 +35.1%
Gross Margin 100% +116.8%
EBITDA Margin -421.56% +52.5%
Operating Margin -446.86% +53.0%
Net Margin -437.97% +52.6%
ROE -149.03% -50.9%
ROIC -866.75% -306.1%
Debt/Equity 0.51 +28.0%
Interest Coverage -52.14 -24.5%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong 5Y sales CAGR of 21.8%
✓Trading at only 0.9x book value

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Weak momentum: RS Rating 4 (bottom 4%)
✗Shares diluted 23.1% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y21.84%

3Y-14.66%

TTM-25.51%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM15.53%

EPS CAGR

10Y-

5Y-

3Y-

TTM49.02%

ROCE

10Y Avg-71.46%

5Y Avg-81.28%

3Y Avg-95.55%

Latest-131.85%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.33B	9.92	70.86	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	720.1M	4.25	11.18	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	881.27M	2.22	-1.73	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	572.64M	7.30	-2.38			-117.82%	0.18
NKTRNektar Therapeutics	719.28M	35.36	-4.07	9.22%	-192.87%	-141.9%	1.69
IMNMImmunome, Inc.	2.52B	22.85	-4.57	-35.5%	-23.01%	-84.4%	0.03
IBRXImmunityBio, Inc.	3.89B	3.95	-6.37	22.71%	-422.28%
NRIXNurix Therapeutics, Inc.	1.91B	18.86	-6.55	-29.15%	-292.5%	-65.76%	0.05

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	1.14M	3.46M	3.15M	14.94M	1.25M	5.49M	9.29M
Revenue Growth %	-	-	-	-	2.03%	-0.09%	3.74%	-0.92%	3.41%	0.69%
Cost of Goods Sold+	44.81K	202.09K	419.57K	28.54M	27.49M	33.55M	-1.78M	0	38.1M	0
COGS % of Revenue	-	-	-	24.98%	7.95%	10.63%	-0.12%	-	6.94%	-
Gross Profit+	-44.81K	-202.09K	-419.57K	-27.4M	-24.03M	-30.39M	16.72M	1.25M	-32.61M	9.29M
Gross Margin %	-	-	-	-23.98%	-6.95%	-9.63%	1.12%	1%	-5.94%	1%
Gross Profit Growth %	-	-3.51%	-1.08%	-64.31%	0.12%	-0.26%	1.55%	-0.93%	-27.19%	1.28%
Operating Expenses+	1.93M	7.66M	23.23M	39.84M	12.74M	14.65M	60.43M	54.47M	19.54M	50.79M
OpEx % of Revenue	-	-	-	34.87%	3.68%	4.64%	4.04%	43.75%	3.56%	5.47%
Selling, General & Admin	425.08K	1.97M	4.33M	11.3M	12.74M	14.65M	17.31M	16.17M	16.68M	14.59M
SG&A % of Revenue	-	-	-	9.89%	3.68%	4.64%	1.16%	12.99%	3.04%	1.57%
Research & Development	1.5M	5.69M	18.9M	28.54M	27.49M	33.55M	41.35M	38.58M	40.8M	36.3M
R&D % of Revenue	-	-	-	24.98%	7.95%	10.63%	2.77%	30.99%	7.43%	3.91%
Other Operating Expenses	0	0	0	165.34K	-27.49M	-33.55M	1.78M	-277K	-37.94M	-93K
Operating Income+	-1.93M	-7.66M	-23.23M	-38.7M	-36.77M	-45.04M	-43.71M	-53.23M	-52.15M	-41.5M
Operating Margin %	-	-	-	-33.87%	-10.63%	-14.28%	-2.93%	-42.75%	-9.5%	-4.47%
Operating Income Growth %	-	-2.97%	-2.03%	-0.67%	0.05%	-0.23%	0.03%	-0.22%	0.02%	0.2%
EBITDA+	-1.88M	-7.46M	-22.81M	-37.94M	-35.96M	-43.99M	-45.49M	-51.42M	-48.71M	-39.15M
EBITDA Margin %	-	-	-	-33.2%	-10.4%	-13.94%	-3.04%	-41.3%	-8.87%	-4.22%
EBITDA Growth %	-	-2.96%	-2.06%	-0.66%	0.05%	-0.22%	-0.03%	-0.13%	0.05%	0.2%
D&A (Non-Cash Add-back)	44.81K	202.09K	419.57K	760.01K	810.78K	1.06M	-1.78M	1.81M	3.44M	2.35M
EBIT	-1.93M	-7.66M	-23.23M	-38.7M	-36.77M	-45.04M	-43.67M	-52.3M	-49.49M	-39.88M
Net Interest Income+	0	0	0	376.01K	482.79K	463.91K	45.9K	215K	1.42M	826K
Interest Income	0	52	35	376.01K	419K	463.91K	45.9K	928.24K	2.66M	1.62M
Interest Expense	0	0	0	0	0	0	0	713.82K	1.25M	796K
Other Income/Expense	0	52	35	541.35K	482.79K	463.91K	45.9K	215K	1.42M	826K
Pretax Income+	-1.93M	-7.66M	-23.23M	-38.16M	-36.29M	-44.58M	-43.67M	-53.01M	-50.73M	-40.67M
Pretax Margin %	-	-	-	-33.39%	-10.49%	-14.13%	-2.92%	-42.58%	-9.24%	-4.38%
Income Tax+	0	0	0	825K	412.5K	206.25K	495K	0	0	0
Effective Tax Rate %	1%	1%	1%	1.02%	1.01%	1%	1.01%	1%	1%	1%
Net Income+	-1.93M	-7.66M	-23.23M	-38.98M	-36.7M	-44.78M	-44.16M	-53.01M	-50.73M	-40.67M
Net Margin %	-	-	-	-34.12%	-10.61%	-14.2%	-2.96%	-42.58%	-9.24%	-4.38%
Net Income Growth %	-	-2.97%	-2.03%	-0.68%	0.06%	-0.22%	0.01%	-0.2%	0.04%	0.2%
Net Income (Continuing)	-1.93M	-7.66M	-23.23M	-38.98M	-36.7M	-44.78M	-44.16M	-53.01M	-50.73M	-40.67M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.26	-0.37	-1.13	-1.94	-1.66	-1.56	-1.41	-1.49	-1.11	-0.72
EPS Growth %	-	-0.42%	-2.05%	-0.72%	0.14%	0.06%	0.1%	-0.06%	0.26%	0.35%
EPS (Basic)	-0.26	-0.37	-1.13	-1.94	-1.66	-1.56	-1.41	-1.49	-1.11	-0.72
Diluted Shares Outstanding	7.35M	20.64M	20.64M	20.13M	22.04M	28.69M	31.29M	35.65M	45.75M	56.33M
Basic Shares Outstanding	7.35M	20.64M	20.64M	20.13M	22.04M	28.69M	31.29M	35.65M	45.75M	56.33M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	6.51M	15.14M	65.07M	40.61M	61.02M	87.53M	68.47M	77.19M	51.45M	25.14M
Cash & Short-Term Investments	6.46M	14.98M	63.58M	39.21M	59.41M	84.87M	64.37M	76.29M	48.51M	23.39M
Cash Only	6.41M	14.93M	63.53M	20.8M	44.29M	74.87M	64.37M	51.61M	48.51M	22.46M
Short-Term Investments	50K	50.03K	50.07K	18.41M	15.12M	10M	0	24.68M	0	929K
Accounts Receivable	0	0	0	0	754.9K	1.42M	3.14M	57K	1.7M	945K
Days Sales Outstanding	-	-	-	-	79.67	164.02	76.77	16.71	112.89	37.14
Inventory	0	0	225.5K	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	196.17	-	-	-	-	-	-	-
Other Current Assets	0	0	453.49K	104.07K	0	0	0	841K	1.24M	0
Total Non-Current Assets+	807.97K	1.14M	1.89M	4.75M	10.58M	12.01M	14.93M	14.1M	10.08M	7.05M
Property, Plant & Equipment	709.47K	1.02M	1.69M	2.78M	7.18M	8.88M	11.92M	10.7M	7.12M	4.84M
Fixed Asset Turnover	-	-	-	0.41x	0.48x	0.36x	1.25x	0.12x	0.77x	1.92x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	175K	0	11.67K	0	0	0	0	0
Long-Term Investments	0	0	0	150K	0	0	150K	0	151K	0
Other Non-Current Assets	98.5K	117K	23.28K	1.82M	3.38M	3.12M	2.86M	3.39M	2.81M	2.21M
Total Assets+	7.31M	16.28M	66.95M	45.36M	71.61M	99.53M	83.4M	91.28M	61.53M	32.19M
Asset Turnover	-	-	-	0.03x	0.05x	0.03x	0.18x	0.01x	0.09x	0.29x
Asset Growth %	-	1.23%	3.11%	-0.32%	0.58%	0.39%	-0.16%	0.09%	-0.33%	-0.48%
Total Current Liabilities+	342.2K	1.07M	5.35M	6.22M	11.66M	16.32M	12.79M	11.55M	17.08M	13.69M
Accounts Payable	139.63K	523.81K	1.33M	2.04M	882.67K	2.07M	2.59M	2.73M	3.5M	2.82M
Days Payables Outstanding	1.14K	946.09	1.16K	26.03	11.72	22.53	-531.84	-	33.54	-
Short-Term Debt	0	0	0	0	0	0	1.97M	1.96M	3.96M	4.33M
Deferred Revenue (Current)	0	0	623.85K	1000K	0	1000K	645.35K	0	1000K	0
Other Current Liabilities	45.45K	109.09K	2.54M	1.58M	4.1M	1.96M	38.31K	2.27M	1.92M	85K
Current Ratio	19.01x	14.18x	12.17x	6.53x	5.24x	5.36x	5.35x	6.68x	3.01x	1.84x
Quick Ratio	19.01x	14.18x	12.13x	6.53x	5.24x	5.36x	5.35x	6.68x	3.01x	1.84x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	34.09K	36.36K	0	5.17M	5.37M	4.31M	5.12M	14.05M	7.36M	1M
Long-Term Debt	0	0	0	0	0	0	0	8.04M	4.2M	0
Capital Lease Obligations	0	0	0	0	1.35M	2.37M	5.12M	6.02M	3.16M	1M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	34.09K	36.36K	0	0	4.02M	0	0	0	0	1
Total Liabilities	376.3K	1.1M	5.35M	11.39M	17.02M	20.62M	17.91M	25.6M	24.45M	14.69M
Total Debt+	0	0	2.5M	0	5.8M	7.15M	12.02M	19.32M	14.7M	8.88M
Net Debt	-6.41M	-14.93M	-61.03M	-20.8M	-38.49M	-67.72M	-52.35M	-32.3M	-33.82M	-13.58M
Debt / Equity	-	-	0.04x	-	0.11x	0.09x	0.18x	0.29x	0.40x	0.51x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-	-	-74.56x	-41.89x	-52.14x
Total Equity+	6.94M	15.17M	61.61M	33.97M	54.58M	78.91M	65.49M	65.68M	37.09M	17.5M
Equity Growth %	-	1.19%	3.06%	-0.45%	0.61%	0.45%	-0.17%	0%	-0.44%	-0.53%
Book Value per Share	0.94	0.74	2.98	1.69	2.48	2.75	2.09	1.84	0.81	0.31
Total Shareholders' Equity	6.94M	15.17M	61.61M	33.97M	54.58M	78.91M	65.49M	65.68M	37.09M	17.5M
Common Stock	7.35K	10.64K	20.13K	20.7K	26.56K	30.35K	32.2K	43K	47K	62K
Retained Earnings	-1.93M	-9.59M	-32.82M	-71.8M	-108.5M	-153.29M	-197.45M	-250.46M	-301.19M	-341.86M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-44.81K	-246.9K	-661.15K	-10.96K	-10.32K	7.13K	0	-96K	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-1.66M	-5.97M	-12.19M	-26.41M	-30.8M	-32.49M	-38.84M	-41.81M	-39.96M	-36.33M
Operating CF Margin %	-	-	-	-23.11%	-8.91%	-10.3%	-2.6%	-33.58%	-7.28%	-3.91%
Operating CF Growth %	-	-2.6%	-1.04%	-1.17%	-0.17%	-0.06%	-0.2%	-0.08%	0.04%	0.09%
Net Income	-1.93M	-7.66M	-23.23M	-38.98M	-36.7M	-44.78M	-44.16M	-53.01M	-50.73M	-40.67M
Depreciation & Amortization	44.81K	202.09K	419.57K	760.01K	5.17M	-3.15M	-1.78M	1.81M	3.44M	2.35M
Stock-Based Compensation	0	889.56K	2.78M	7.17M	6.52M	10.48M	11.52M	9.5M	8.18M	6.85M
Deferred Taxes	0	0	10.68K	79.86K	-18.19K	0	0	0	0	0
Other Non-Cash Items	79.55K	65.91K	4.93M	345.1K	-4.28M	-479.54K	-26.13K	-454K	90K	74K
Working Capital Changes	146.8K	532.32K	2.91M	4.21M	-1.49M	5.43M	-4.39M	356K	-934K	-4.92M
Change in Receivables	0	0	0	0	-754.9K	-662.58K	-1.73M	3.08M	-1.64M	753K
Change in Inventory	0	0	0	0	-509.8K	0	0	0	0	0
Change in Payables	177.81K	0	561.59K	376.15K	-1.15M	741.26K	520.4K	83K	770K	-678K
Cash from Investing+	-804.29K	-516.01K	-1.2M	-20.35M	3.45M	4.46M	9.11M	-24.61M	25M	32K
Capital Expenditures	-754.29K	-515.98K	-1.2M	-1.85M	-46.35K	-595.26K	-913.04K	-171K	0	-66K
CapEx % of Revenue	-	-	-	1.62%	0.01%	0.19%	0.06%	0.14%	-	0.01%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-50K	-33	-35	-18.5M	0	0	21.55K	6K	2K	98K
Cash from Financing+	8.87M	15.01M	62M	4.18M	50.79M	58.61M	19.23M	53.66M	11.86M	10.24M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	1K	0	9.01K	12.5K	1.79M	1.93M	1.85M	4.36M	473K	18K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-2.41M	-6.48M	-13.4M	-28.27M	-30.84M	-33.09M	-39.75M	-41.98M	-39.96M	-36.4M
FCF Margin %	-	-	-	-24.74%	-8.92%	-10.49%	-2.66%	-33.72%	-7.28%	-3.92%
FCF Growth %	-	-1.69%	-1.07%	-1.11%	-0.09%	-0.07%	-0.2%	-0.06%	0.05%	0.09%
FCF per Share	-0.33	-0.31	-0.65	-1.40	-1.40	-1.15	-1.27	-1.18	-0.87	-0.65
FCF Conversion (FCF/Net Income)	0.86x	0.78x	0.52x	0.68x	0.84x	0.73x	0.88x	0.79x	0.79x	0.89x
Interest Paid	0	0	0	0	0	0	0	570K	1M	669K
Taxes Paid	0	0	0	825K	412.5K	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-27.8%	-69.27%	-60.52%	-81.57%	-82.88%	-67.1%	-61.16%	-80.82%	-98.73%	-149.03%
Return on Invested Capital (ROIC)	-	-1469.1%	-4237.96%	-422.31%	-188.49%	-247.66%	-269.45%	-171.6%	-213.43%	-866.75%
Gross Margin	-	-	-	-2398.16%	-694.82%	-963.48%	111.9%	100%	-593.93%	100%
Net Margin	-	-	-	-3411.53%	-1061.18%	-1419.79%	-295.56%	-4257.83%	-924.1%	-437.97%
Debt / Equity	-	-	0.04x	-	0.11x	0.09x	0.18x	0.29x	0.40x	0.51x
Interest Coverage	-	-	-	-	-	-	-	-74.56x	-41.89x	-52.14x
FCF Conversion	0.86x	0.78x	0.52x	0.68x	0.84x	0.73x	0.88x	0.79x	0.79x	0.89x
Revenue Growth	-	-	-	-	202.67%	-8.79%	373.68%	-91.67%	340.96%	69.16%

Frequently Asked Questions

Growth & Financials

Cue Biopharma, Inc. (CUE) reported $7.1M in revenue for fiscal year 2024.

Cue Biopharma, Inc. (CUE) grew revenue by 69.2% over the past year. This is strong growth.

Cue Biopharma, Inc. (CUE) reported a net loss of $37.7M for fiscal year 2024.

Dividend & Returns

Cue Biopharma, Inc. (CUE) has a return on equity (ROE) of -149.0%. Negative ROE indicates the company is unprofitable.

Cue Biopharma, Inc. (CUE) had negative free cash flow of $29.8M in fiscal year 2024, likely due to heavy capital investments.